FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.
News|Slideshows|September 26, 2025
Adult Immunization in the US: Status, Gaps, and Forward Strategy
Author(s)Grace Halsey
Fact checked by: Sydney Jennings
Adult vaccine-preventable diseases cost $26.5B annually in the US. See key gaps, barriers, and strategies primary care physicians can use to boost immunization.
Advertisement
Advertisement
Related to this article
In a pilot study of 20 midlife women with vasomotor symptoms, an AI-enabled VR program delivering CBT showed early feasibility and acceptability.
Capsule-sponge DNA methylation test boosts Barrett’s screening access, showing high accuracy, strong tolerability, and promise for primary care triage to endoscopy.
ACOG's new guideline covers hormone therapy timing, neurokinin receptor antagonists, SSRIs/SNRIs, and nonpharmacologic options for menopause symptoms.
Post hoc LUCENT-2 and VIVID-1 analyses show more mirikizumab-treated patients reached steroid-free composite remission in UC and Crohn disease at 1 year.
The FDA granted Breakthrough Device designation to Natera's cell-free DNA multi-cancer early detection assay. What it means for primary care.
Most adolescents with sporadic colorectal cancer present with stage III or IV disease, and few have a family history, per data presented at AAP 2026.
Freenome reports 18.2% sensitivity for advanced precancerous lesions and 80.4% for colorectal cancer with its updated blood screening test.
Advertisement
Advertisement
Trending on Patient Care Online
1
Capsule-Sponge Testing Could Help Close the Barrett’s Screening Gap: An Expert Q&A
2
ACOG Issues Expanded Guideline on Managing Menopause-Related Vasomotor, Sleep, and Mood Symptoms
3
Actigraphy and Objective Sleep Outcomes in Menopause VMS Treatment
4
Mirikizumab Linked to Higher Rates of Corticosteroid-Free Composite Remission in UC and Crohn Disease
5